| Followers | 258 |
| Posts | 19732 |
| Boards Moderated | 0 |
| Alias Born | 10/03/2004 |
Monday, August 06, 2007 3:42:15 PM
Correction: 2007 Biomedical Advanced Research and Development Authority (BARDA) Industry Day
WHERE:
Fairmont Washington DC, 2401 M Street, NW, Washington, DC 20037
WHEN:
August 3, 2007
WHY
The goal of the 2007 BARDA Industry Day is to provide an open forum for companies interested in working with the Federal Government to showcase technological advances in medical countermeasures to manmade and naturally occurring threats. Representatives from companies who have registered as presenters will demonstrate the progress of current activities in advanced research and development of medical countermeasures that will contribute to the success of the HHS Pandemic Influenza Plan, Project BioShield, BARDA, and the HHS PHEMCE Strategy and Implementation Plan.
The 2007 BARDA Industry day will consist of concurrent breakout sessions on the following topics: vaccines, therapeutics, medical diagnostic products, and non-pharmaceutical countermeasures. During these breakout sessions, industry stakeholders will present their product information to representatives from throughout the federal government, international agencies, industry, and academia
HHS looks forward to receiving valuable input from all participants during the HHS BARDA Industry Day.
CALL FOR PRESENTERS
If your company is interested in presenting information on a vaccine, therapeutic, medical diagnostic product, or non-pharmaceutical countermeasure, click here to see guidelines on submitting abstracts.
REGISTRATION:
Click Here to register for the 2007 BARDA Industry Day.
[Sorry, I had this event confused with something else. This was an open forum with BRADA officials in attendance for the breakout sessions. --Doc FG]
WHERE:
Fairmont Washington DC, 2401 M Street, NW, Washington, DC 20037
WHEN:
August 3, 2007
WHY
The goal of the 2007 BARDA Industry Day is to provide an open forum for companies interested in working with the Federal Government to showcase technological advances in medical countermeasures to manmade and naturally occurring threats. Representatives from companies who have registered as presenters will demonstrate the progress of current activities in advanced research and development of medical countermeasures that will contribute to the success of the HHS Pandemic Influenza Plan, Project BioShield, BARDA, and the HHS PHEMCE Strategy and Implementation Plan.
The 2007 BARDA Industry day will consist of concurrent breakout sessions on the following topics: vaccines, therapeutics, medical diagnostic products, and non-pharmaceutical countermeasures. During these breakout sessions, industry stakeholders will present their product information to representatives from throughout the federal government, international agencies, industry, and academia
HHS looks forward to receiving valuable input from all participants during the HHS BARDA Industry Day.
CALL FOR PRESENTERS
If your company is interested in presenting information on a vaccine, therapeutic, medical diagnostic product, or non-pharmaceutical countermeasure, click here to see guidelines on submitting abstracts.
REGISTRATION:
Click Here to register for the 2007 BARDA Industry Day.
[Sorry, I had this event confused with something else. This was an open forum with BRADA officials in attendance for the breakout sessions. --Doc FG]
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM

